When wound healing goes awry: A review of normal and abnormal wound healing, scar pathophysiology, and therapeutics

Journal of Drugs in Dermatology

Volumn 7, Issue 10, 2008, Pages 997-1005

  Watkins, Shannon A ^a   Zippin, Jonathan H ^b  

^a Columbia College of Physicians and Surgeons ^*  (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; SILICONE GEL;

HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SCAR; SKIN; WOUND HEALING;

ANTI-INFLAMMATORY AGENTS; CICATRIX; HUMANS; SILICONE GELS; SKIN; WOUND HEALING;

EID: 59049099131     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Bolognia JL JJ, and Rapini RP. Dermatology. Vol 2. Second ed: Mosby Elsevier; 2008.
2. Deuel TF, Senior RM, Huang JS, Griffin GL. Chemotaxis of monocytes and neutrophils to platelet-derived growth factor. J Clin Invest. Apr 1982;69(4):1046-1049. (Pubitemid 12149184)
3. Uutela M, Wirzenius M, Paavonen K, et al. PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood. Nov 15 2004;104(10):3198-3204. (Pubitemid 39507135)
4. Grinnell F, Billingham RE, Burgess L. Distribution of fibronectin during wound healing in vivo. J Invest Dermatol. Mar 1981;76(3):181-189. (Pubitemid 11153925)
5. Katz MH, Alvarez AF, Kirsner RS, Eaglstein WH, Falanga V. Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. J Am Acad Dermatol. Dec 1991;25(6 Pt 1):1054-1058.
6. Parks WC. Matrix metalloproteinases in repair. Wound Repair Regen. Nov-Dec 1999;7(6):423-432. (Pubitemid 30027564)
7. Sun TT, Cotsarelis G, Lavker RM. Hair follicular stem cells: the bulge-activation hypothesis. J Invest Dermatol. May 1991;96(5):77S-78S.
8. Abercrombie M FM, James DW. Wound contraction in relation to collagen formation in scorbutic guinea-pigs. J Embryol Exp Morphol. 1956;4:167-175.
9. Butler PD, Longaker MT, Yang GP. Current progress in keloid research and treatment. J Am Coll Surg. Apr 2008;206(4):731-741.
10. Atiyeh BS, Costagliola M, Hayek SN. Keloid or hypertrophic scar: the controversy: review of the literature. Ann Plast Surg. Jun 2005;54(6):676-680. (Pubitemid 40726841)
11. Child FJ, Fuller LC, Higgins EM, Du Vivier AW. A study of the spectrum of skin disease occurring in a black population in south-east London. Br J Dermatol. Sep 1999;141(3):512-517. (Pubitemid 29448414)
12. English RS, Shenefelt PD. Keloids and hypertrophic scars. Dermatol Surg. Aug 1999;25(8):631-638. (Pubitemid 29383470)
13. Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol. Feb 2002;46(2 Suppl Understanding):S63-97.
14. Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. Oct 1999;104(5):1435-1458. (Pubitemid 29466295)
15. Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today. Jan 1998;4(1):19-24. (Pubitemid 28124795)
16. Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on scar management. Plast Reconstr Surg. Aug 2002;110(2):560-571. (Pubitemid 34815962)
17. Funayama E, Chodon T, Oyama A, Sugihara T. Keratinocytes promote proliferation and inhibit apoptosis of the underlying fibroblasts: an important role in the pathogenesis of keloid. J Invest Dermatol. Dec 2003;121(6):1326- 1331. (Pubitemid 38005480)
18. Kose O, Waseem A. Keloids and hypertrophic scars: are they two different sides of the same coin? Dermatol Surg. Mar 2008;34(3):336-346. (Pubitemid 351316825)
19. Niessen FB, Schalkwijk J, Vos H, Timens W. Hypertrophic scar formation is associated with an increased number of epidermal Langerhans cells. J Pathol. Jan 2004;202(1):121-129. (Pubitemid 38072853)
20. Garner WL. Epidermal regulation of dermal fibroblast activity. Plast Reconstr Surg. Jul 1998;102(1):135-139. (Pubitemid 28303977)
21. Andriessen MP, Niessen FB, Van de Kerkhof PC, Schalkwijk J. Hypertrophic scarring is associated with epidermal abnormalities: an immunohistochemical study. J Pathol. Oct 1998;186(2):192-200. (Pubitemid 28467830)
22. Machesney M, Tidman N, Waseem A, Kirby L, Leigh I. Activated keratinocytes in the epidermis of hypertrophic scars. Am J Pathol. May 1998;152(5):1133-1141. (Pubitemid 28221864)
23. Satish L, Babu M, Tran KT, Hebda PA, Wells A. Keloid fibroblast responsiveness to epidermal growth factor and activation of downstream intracellular signaling pathways. Wound Repair Regen. Mar-Apr 2004;12(2):183-192. (Pubitemid 38520685)
24. Xia W, Phan TT, Lim IJ, Longaker MT, Yang GP. Differential transcriptional responses of keloid and normal keratinocytes to serum stimulation. J Surg Res. Sep 2006;135(1):156-163. (Pubitemid 44215903)
25. Lee JY, Yang CC, Chao SC, Wong TW. Histopathological differential diagnosis of keloid and hypertrophic scar. Am J Dermatopathol. Oct 2004;26(5):379-384. (Pubitemid 39287358)
26. Chodon T, Sugihara T, Igawa HH, Funayama E, Furukawa H. Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance. Am J Pathol. Nov 2000;157(5):1661-1669.
27. Niessen FB, Andriessen MP, Schalkwijk J, Visser L, Timens W. Keratinocyte-derived growth factors play a role in the formation of hypertrophic scars. J Pathol. Jun 2001;194(2):207-216.
28. Smith P, Mosiello G, Deluca L, Ko F, Maggi S, Robson MC. TGF-beta2 activates proliferative scar fibroblasts. J Surg Res. Apr 1999;82(2):319-323. (Pubitemid 29394140)
29. Wang R, Ghahary A, Shen Q, Scott PG, Roy K, Tredget EE. Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells. Wound Repair Regen. Mar-Apr 2000;8(2):128-137. (Pubitemid 30238326)
30. Bettinger DA, Yager DR, Diegelmann RF, Cohen IK. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg. Oct 1996;98(5):827-833. (Pubitemid 26322164)
31. Lee TY, Chin GS, Kim WJ, Chau D, Gittes GK, Longaker MT. Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg. Aug 1999;43(2):179-184. (Pubitemid 29380019)
32. Polo M, Smith PD, Kim YJ, Wang X, Ko F, Robson MC. Effect of TGF-beta2 on proliferative scar fibroblast cell kinetics. Ann Plast Surg. Aug 1999;43(2):185-190. (Pubitemid 29380020)
33. Zhou LJ, Ono I, Kaneko F. Role of transforming growth factor-beta 1 in fibroblasts derived from normal and hypertrophic scarred skin. Arch Dermatol Res. Oct 1997;289(11):646-652. (Pubitemid 27510829)
34. Calderon M, Lawrence WT, Banes AJ. Increased proliferation in keloid fibroblasts wounded in vitro. J Surg Res. Mar 1996;61(2):343-347. (Pubitemid 26087681)
35. Messadi DV, Le A, Berg S, et al. Expression of apoptosis-associated genes by human dermal scar fibroblasts. Wound Repair Regen. Nov-Dec 1999;7(6):511-517. (Pubitemid 30027574)
36. Tanaka A, Hatoko M, Tada H, Iioka H, Niitsuma K, Miyagawa S. Expression of p53 family in scars. J Dermatol Sci. Feb 2004;34(1):17-24. (Pubitemid 38134469)
37. Teofoli P, Barduagni S, Ribuffo M, Campanella A, De Pita O, Puddu P. Expression of Bcl-2, p53, c-jun and c-fos protooncogenes in keloids and hypertrophic scars. J Dermatol Sci. Dec 1999;22(1):31-37.
38. Wassermann RJ, Polo M, Smith P, Wang X, Ko F, Robson MC. Differential production of apoptosis-modulating proteins in patients with hypertrophic burn scar. J Surg Res. Feb 15 1998;75(1):74-80. (Pubitemid 28247116)
39. Durani P, Bayat A. Levels of evidence for the treatment of keloid disease. J Plast Reconstr Aesthet Surg. 2008;61(1):4-17. (Pubitemid 350199116)
40. Hochman B, Locali RF, Matsuoka PK, Ferreira LM. Intralesional triamcinolone acetonide for keloid treatment: a systematic review. Aesthetic Plast Surg. Jul 2008;32(4):705-709.
41. Robles DT, Moore E, Draznin M, Berg D. Keloids: pathophysiology and management. Dermatol Online J. 2007;13(3):9.
42. Kiil J. Keloids treated with topical injections of triamcinolone acetonide (kenalog). Immediate and long-term results. Scand J Plast Reconstr Surg. 1977;11(2):169-172. (Pubitemid 8289059)
43. Farahnaz F JN, Koroush A. Comparison of therapeutic response of keloids and hypertrophic scars to cryotherapy plus intralesional steroid and bleomycin tattoo. Indian J Dermatol. 2005;50:129-132.
44. Cruz NI, Korchin L. Inhibition of human keloid fibroblast growth by isotretinoin and triamcinolone acetonide in vitro. Ann Plast Surg. Oct 1994;33(4):401-405. (Pubitemid 24320710)
45. Carroll LA, Hanasono MM, Mikulec AA, Kita M, Koch RJ. Triamcinolone stimulates bFGF production and inhibits TGF-beta1 production by human dermal fibroblasts. Dermatol Surg. Aug 2002;28(8):704-709. (Pubitemid 34913279)
46. McKay TL, Gedeon DJ, Vickerman MB, et al. Selective inhibition of angiogenesis in small blood vessels and decrease in vessel diameter throughout the vascular tree by triamcinolone acetonide. Invest Ophthalmol Vis Sci. Mar 2008;49(3):1184-1190.
47. Diegelmann RF, Bryant CP, Cohen IK. Tissue alpha-globulins in keloid formation. Plast Reconstr Surg. Mar 1977;59(3):418-423.
48. Chuang GS, Rogers GS, Zeltser R. Poiseuille's law and large-bore needles: insights into the delivery of corticosteroid injections in the treatment of keloids. J Am Acad Dermatol. Jul 2008;59(1):167-168. (Pubitemid 351832827)
49. Berman B, Viera MH, Amini S, Huo R, Jones IS. Prevention and management of hypertrophic scars and keloids after burns in children. J Craniofac Surg. Jul 2008;19(4):989-1006.
50. Martin-Garcia RF, Busquets AC. Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences: results of an open-label, pilot study. Dermatol Surg. Nov 2005;31:1394-1398.
51. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol. Oct 2002;47(4 Suppl):S209-211.
52. Stashower ME. Successful treatment of earlobe keloids with imiquimod after tangential shave excision. Dermatol Surg. Mar 2006;32(3):380-386.
53. Malhotra AK, Gupta S, Khaitan BK, Sharma VK. Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids. Dermatology. 2007;215(1):63-65. (Pubitemid 46976016)
54. Jacob SE, Berman B, Nassiri M, Vincek V. Topical application of imiquimod 5% cream to keloids alters expression genes associated with apoptosis. Br J Dermatol. Nov 2003;149 Suppl 66:62-65. (Pubitemid 38064523)
55. Sidbury R, Neuschler N, Neuschler E, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol. Nov 2003;121(5):1205-1209. (Pubitemid 37430994)
56. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. May 2004;50(5):714-721. (Pubitemid 38580548)
57. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. May 2004;50(5):722-733. (Pubitemid 38580549)
58. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol. Nov 1997;37(5 Pt 1):755-757. (Pubitemid 27500320)
59. Sclafani AP, Gordon L, Chadha M, Romo T, 3rd. Prevention of earlobe keloid recurrence with postoperative corticosteroid injections versus radiation therapy: a randomized, prospective study and review of the literature. Dermatol Surg. Jun 1996;22(6):569-574. (Pubitemid 26200115)
60. Lee Y, Minn KW, Baek RM, Hong JJ. A new surgical treatment of keloid: keloid core excision. Ann Plast Surg. Feb 2001;46(2):135-140. (Pubitemid 32147323)
61. Chowdri NA, Masarat M, Mattoo A, Darzi MA. Keloids and hypertrophic scars: results with intraoperative and serial postoperative corticosteroid injection therapy. Aust N Z J Surg. Sep 1999;69(9):655-659. (Pubitemid 29422139)
62. Shons AR, Press BH. The treatment of earlobe keloids by surgical excision and postoperative triamcinolone injection. Ann Plast Surg. Jun 1983;10(6):480-482. (Pubitemid 13034637)
63. Lawrence WT. In search of the optimal treatment of keloids: report of a series and a review of the literature. Ann Plast Surg. Aug 1991;27(2):164-178.
64. Darzi MA, Chowdri NA, Kaul SK, Khan M. Evaluation of various methods of treating keloids and hypertrophic scars: a 10-year follow-up study. Br J Plast Surg. Jul 1992;45(5):374-379.
65. Atiyeh BS. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic Plast Surg. Sep-Oct 2007;31(5):468-492; discussion 493-464.
66. Bouzari N, Davis SC, Nouri K. Laser treatment of keloids and hypertrophic scars. Int J Dermatol. Jan 2007;46(1):80-88. (Pubitemid 46029732)
67. Alster TS, Williams CM. Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet. May 13 1995;345(8959):1198-1200.
68. Alster TS. Improvement of erythematous and hypertrophic scars by the 585-nm flashlamp-pumped pulsed dye laser. Ann Plast Surg. Feb 1994;32(2):186-190. (Pubitemid 24057134)
69. Bowes LE, Nouri K, Berman B, et al. Treatment of pigmented hypertrophic scars with the 585 nm pulsed dye laser and the 532 nm frequency-doubled Nd:YAG laser in the Q-switched and variable pulse modes: a comparative study. Dermatol Surg. Aug 2002;28(8):714-719. (Pubitemid 34913281)
70. Shih PY, Chen HH, Chen CH, Hong HS, Yang CH. Rapid Recurrence of Keloid after Pulse Dye Laser Treatment. Dermatol Surg. May 7 2008.
71. Kuo YR, Wu WS, Jeng SF, et al. Activation of ERK and p38 kinase mediated keloid fibroblast apoptosis after flashlamp pulsed-dye laser treatment. Lasers Surg Med. Jan 2005;36(1):31-37.
72. Kuo YR, Wu WS, Jeng SF, et al. Suppressed TGF-beta1 expression is correlated with up-regulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatment. Lasers Surg Med. Jan 2005;36(1):38-42.
73. Levine VJ, Geronemus RG. Adverse effects associated with the 577- and 585-nanometer pulsed dye laser in the treatment of cutaneous vascular lesions: a study of 500 patients. J Am Acad Dermatol. Apr 1995;32(4):613-617.
74. Lupton JR, Alster TS. Laser scar revision. Dermatol Clin. Jan 2002;20(1):55-65. (Pubitemid 34116819)
75. Bernestein LJ, Geronemus RG. Keloid formation with the 585-nm pulsed dye laser during isotretinoin treatment. Arch Dermatol. Jan 1997;133(1):111-112. (Pubitemid 27044323)
76. Sawada Y, Sone K. Treatment of scars and keloids with a cream containing silicone oil. Br J Plast Surg. Nov 1990;43(6):683-688. (Pubitemid 20374059)
77. Mustoe TA. Evolution of silicone therapy and mechanism of action in scar management. Aesthetic Plast Surg. Jan 2008;32(1):82-92.
78. O'Brien L, Pandit A. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev. 2006(1):CD003826.
79. Zhang GY, Yi CG, Li X, et al. Inhibition of vascular endothelial growth factor expression in keloid fibroblasts by vector-mediated vascular endothelial growth factor shRNA: a therapeutic potential strategy for keloid. Arch Dermatol Res. Apr 2008;300(4):177-184.
80. Ong CT, Khoo YT, Tan EK, et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol. Jan 2007;211(1):95-108. (Pubitemid 46092034)
81. Chu Y, Guo F, Li Y, Li X, Zhou T, Guo Y. A novel truncated TGF-beta receptor II downregulates collagen synthesis and TGF-beta I secretion of keloid fibroblasts. Connect Tissue Res. 2008;49(2):92-98.
82. Naim R, Naumann A, Barnes J, et al. Transforming growth factor-beta1-antisense modulates the expression of hepatocyte growth factor/scatter factor in keloid fibroblast cell culture. Aesthetic Plast Surg. Mar 2008;32(2):346-352.
83. Sadick H, Herberger A, Riedel K, et al. TGF-beta1 antisense therapy modulates expression of matrix metalloproteinases in keloid-derived fibroblasts. Int J Mol Med. Jul 2008;22(1):55-60.